This large-scale pharmacovigilance study, analyzing 7,176 reports, revealed substantial heterogeneity in pneumonia risk profiles among different TNF-α inhibitors, with important implications for clinical decision-making and patient management strategies. This evidence concerns the gene TNF and pneumonia.